Spinal Xanthomatosis
Neurol 95:e1615-e1616, Valencia-Sanchez, C.,et al, 2020
Clinical Reasoning: A Case of Treatable Spastic Paraparesis
Neurol 79: e50-e53, McKinnon, J.H. & Bosch E.P., 2012
Long-Term Treatment Effect in Cerebrotendinous Xanthomatosis Depends on Age at Treatment Start
Neurol 92:e83-e95, Stelten, B.M.L.,et al, 2019
Presence of Diarrhea and Absence of Tendon Xanthomas in Patients With Cerebrotendinous Xanthomatosis
Arch Neurol 57:520-524, Verrips,A.,et al, 2000
Cerebrotendinous Xanthomatosis:Molecular Diagnosis Enables Presymptomatic Detection of a Treatable Disease
Neurol 44:288-290, Meiner,V.,et al, 1994
Evoked Potentials in Cerebrotendinous Xanthomatosis and Effect Induced by Chenodeoxycholic Acid
Arch Neurol 49:469-475, Mondelli,M.,et al, 1992
Cerebrotendinous Xanthomatosis:Treatments with Simvastatin, Lovastatin, & Chenodeoxycholic Acid in 3 Siblings
Neurol 41:434-436, Peynet,J.,et al, 1991
Cerebrotendinous Xanthomatosis:Clinical and MRI Study (A Case Report)
JNNP 53:76-78, Fiorelli,M.,et al, 1990
Increased Concentrations of Cholestanol & Apolipoprotein B in CSF with Cerebrotendinous Xanthomatosis
NEJM 316:1233-1238, Salen,G.,et al, 1987
Magnetic Resonance Imaging in Cerebrotendinous Xanthomatosis
Neurol 36:124-126, Swanson,P.D.&Cromwell,L.D., 1986
Treatment of Cerebrotendinous Xanthomatosis with Chenodeoxycholic Acid
Ann Neurol 18:517-518, Pedley,T.A.,et al, 1985
Long-Term Treatment of Cerebrotendinous Xanthomatosis with Chenodeoxycholic Acid
NEJM 311:1649-1652, Berginer,V.M.,et al, 1984